Bactiguard appoints new distributor in Mexico
Bactiguard signs distribution agreement for Mexico with Degasa, a well-established family owned company in the second largest market in Latin America.
“Degasa is a strong distributor in the attractive Mexican market, with both the resources and competence required to drive a successful market introduction”, says Christian Kinch, CEO at Bactiguard.
Mexico in the second largest market in Latin America with its 120 million inhabitants, only succeeded by Brazil. Degasa is a family owned company with no less than 10 country-wide sales offices that cover the entire country, and are well established in the healthcare sector since more than 50 years. The company represents several major international brands and are active in all major sectors and sales channels, such as public and private hospitals, home care and pharmacies.
Previously, Bactiguard had a distribution agreement with the Argentinian company Promedon for several markets in Latin America. The contract was terminated in 2017 and Bactiguard signed a new agreement with Biodina for Brazil. The new agreement with Degasa for Mexico is in line with Bactiguard’s expansion plans in a few, significant markets in the region.
Degasa will now initiate the process of being registered as Bactiguard’s distributor with the Mexican authorities, which must be completed before sales can commence. This process is expected to take a couple of months.
For further information, please contact:
Nina Nilsson, SVP Sales and Marketing, +46 702 14 87 49
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives on www.bactiguard.com